B-Type Natriuretic Peptide Predicts Responses to Indomethacin in Premature Neonates with Patent Ductus Arteriosus

Journal of Pediatrics

Volumn 157, Issue 1, 2010, Pages 79-84

  Hsu, Jong Hau ^a,b,c   Yang, San Nan ^a,c   Chen, Hsiu Lin ^a,d   Tseng, Hsing I ^a   Dai, Zen Kong ^a,b   Wu, Jiunn Ren ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; INDOMETACIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TREATMENT FAILURE; ECHOCARDIOGRAPHY; FEMALE; HEART SURGERY; HUMAN; INFANT; LIGATION; MALE; PATENT DUCTUS ARTERIOSUS; PREDICTION; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

CARDIOVASCULAR AGENTS; CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS, PATENT; FEMALE; GESTATIONAL AGE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PREGNANCY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953292583     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.12.045     Document Type: Article

References (29)

1. Rojas M.A., Gonzalez A., Bancalari E., Claure N., Poole C., and Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 126 (1995) 605-610
2. Kluckow M., and Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 137 (2000) 68-72
3. Hammerman C. Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 22 (1995) 457-479
4. Cotton R.B., Stahlman M.T., Kovar I., and Catterton W.Z. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 92 (1978) 467-473
5. Betkerur M.V., Yeh T.F., Miller K., Glasser R.J., and Pildes R.S. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics 68 (1981) 99-102
6. Grosfeld J.L., Chaet M., Molinari F., Engle W., Engum S.A., West K.W., et al. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg 224 (1996) 350-355
7. Edwards A.D., Wyatt J.S., Richardson C., Potter A., Cope M., Delpy D.T., et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet 335 (1990) 1491-1495
8. Itabashi K., Ohno T., and Nishida H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr 143 (2003) 203-207
9. Merritt T.A., DiSessa T.G., Feldman B.H., Kirkpatrick S.E., Gluck L., and Friedman W.F. Closure of the patent ductus arteriosus with ligation and indomethacin: a consecutive experience. J Pediatr 93 (1978) 639-646
10. Siassi B., Blanco C., Cabal L.A., and Coran A.G. Incidence and clinical features of patent ductus arteriosus in low-birthweight infants: a prospective analysis of 150 consecutively born infants. Pediatrics 57 (1976) 347-351
11. Yeh T.F., Luken J.A., Thalji A., Raval D., Carr I., and Pildes R.S. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus-a double-blind controlled study. J Pediatr 98 (1981) 137-145
12. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
13. Puddy V.F., Amirmansour C., Williams A.F., and Singer D.R. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 103 (2002) 75-77
14. Sanjeev S., Pettersen M., Lua J., Thomas R., Shankaran S., and L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 25 (2005) 709-713
15. Attridge J.T., Kaufman D.A., and Lim D.S. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 94 (2009) F178-F182
16. Czernik C., Lemmer J., Metze B., Koehne P.S., Mueller C., and Obladen M. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks. Pediatr Res 64 (2008) 286-290
17. Young T.E., and Mangum B. Neofax: a manual of drugs used in neonatal care. 20th ed. (2007), Thomson Healthcare, Montvale
18. Hsu J.H., Keller R.L., Chikovani O., Cheng H., Hollander S.A., Karl T.R., et al. B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery. J Thorac Cardiovasc Surg 134 (2007) 939-945
19. Flynn P.A., da Graca R.L., Auld P.A., Nesin M., and Kleinman C.S. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 147 (2005) 38-42
20. Choi B.M., Lee K.H., Eun B.L., Yoo K.H., Hong Y.S., Son C.S., et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 115 (2005) e255-e261
21. Price J.F., Thomas A.K., Grenier M., Eidem B.W., O'Brian Smith E., Denfield S.W., et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 114 (2006) 1063-1069
22. Chikovani O., Hsu J.H., Keller R., Karl T.R., Azakie A., Adatia I., et al. B-type natriuretic peptide levels predict outcomes for children on extracorporeal life support after cardiac surgery. J Thorac Cardiovasc Surg 134 (2007) 1179-1187
23. Hsu J.H., Oishi P.E., Keller R.L., Chikovani O., Karl T.R., Azakie A., et al. Perioperative B-type natriuretic peptide levels predict outcome after bidirectional cavopulmonary anastomosis and total cavopulmonary connection. J Thorac Cardiovasc Surg 135 (2008) 746-753
24. O'Mara P.W., Poole S.D., Brown N., Ding T., Paria B., and Reese J. Regulation of the fetal and newborn ductus arteriosus by natriuretic peptides. E-PAS 59 (2006) 2875.314
25. Toyoshima K., Momma K., Imamura S., and Nakanishi T. In vivo dilatation of the postnatal ductus arteriosus by atrial natriuretic peptide in the rat. Neonatology 92 (2007) 139-144
26. Chiurchiu V., Izzi V., D'Aquilio F., Carotenuto F., Di Nardo P., and Baldini P.M. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept 148 (2008) 26-32
27. Waleh N., Kajino H., Marrache A.M., Ginzinger D., Roman C., Seidner S.R., et al. Prostaglandin E2-mediated relaxation of the ductus arteriosus: effects of gestational age on G protein-coupled receptor expression, signaling, and vasomotor control. Circulation 110 (2004) 2326-2332
28. Sperandio M., Beedgen B., Feneberg R., Huppertz C., Brussau J., Poschl J., et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 116 (2005) 1361-1366
29. Van Overmeire B., Van de Broek H., Van Laer P., Weyler J., and Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 138 (2001) 205-211